Diseases & Longevity · File 23

Breast cancer. 1st global cancer incidence — and with modifiable factors.

Breast cancer is the 1st cancer incidence cause in women globally — ~2.3 million new cases per year (GLOBOCAN 2022). The trajectory has genetic components (BRCA1/2 and others), hormonal (early menarche, nulliparity, late menopause, hormone therapy), and modifiable (postmenopausal obesity, alcohol, physical inactivity). Mammographic screening and high-risk identification change prognosis.

Why the breast cancer conversation goes beyond screening

Approximately 1 in 8 women in high-income countries will develop breast cancer in their lifetime. Mortality has decreased in HICs thanks to mammographic screening and adjuvant therapies — but the modern conversation is not reduced to "do the mammogram". It has three components:

(1) Risk-appropriate screening — biennial mammography 40-74 (USPSTF 2024), supplementary breast MRI in high risk, ultrasound in dense breasts. (2) High-risk identification — BRCA1/2 and other germline mutations (PALB2, CHEK2, ATM), family history, Tyrer-Cuzick / Gail score. (3) Modifiable factors — postmenopausal obesity (IARC group 1), alcohol (linear dose-dependent association), physical inactivity, prolonged hormone replacement therapy. Longevity medicine operates on all three.

Screening + BRCA risk stratification + modifiable factors — those are the three axes. None is optional, and all three are real longevity medicine.
New cases · 2022 global

The global weight, in numbers

Data come from GLOBOCAN, USPSTF, ASCO, ESMO, and meta-analyses on modifiable factors. They confirm the three intervention opportunities.

  • Global incidence

    1ra en mujeres

    GLOBOCAN 2022: ~2.3 million new cases and ~670k annual deaths. It's the 1st cancer incidence cause in women globally, and top 4 of female cancer mortality.
    — GLOBOCAN 2022

  • BRCA1/2

    ~5-10% de casos

    BRCA1 and BRCA2 explain approximately 5-10% of breast cancers. Lifetime risk in carriers exceeds 60-70% for BRCA1 and 45-55% for BRCA2 — requires intensified screening and multidisciplinary management.
    — Kuchenbaecker et al., JAMA 2017

  • Mammographic screening

    USPSTF 2024 · 40-74 bienal

    USPSTF 2024 updated indication to biennial mammography 40-74 (previously 50-74). Screening in this range consistently reduces breast cancer mortality in trials and cohorts.
    — USPSTF 2024 Recommendation Statement

  • Modifiable factors

    Obesidad postmen. + alcohol + sed.

    Postmenopausal obesity (IARC group 1), alcohol (linear association: ~7% increase per drink/day), physical inactivity, prolonged hormone replacement therapy, and smoking modify incidence. Together explain a significant attributable fraction.
    — Lauby-Secretan, NEJM 2016; Allen et al., JNCI 2009

Chap. 03 · Post-diagnosis trajectory

Survival, quality of life, and comorbidities

Breast cancer has high survival when detected early — but treatment comorbidities (cardiotoxicity, sarcopenia, depression) are the modern post-cancer longevity conversation.

  • 5-year survival

    >85% en HIC

    Global 5-year survival exceeds 85% in HICs for all combined stages, and >95% in stage I. That's why early detection directly changes prognosis.
    — SEER; Cancer Statistics 2024

  • Post-treatment cardiotoxicity

    Antraciclinas + RT + trastuzumab

    Anthracyclines, trastuzumab, and radiotherapy can generate short and long-term cardiotoxicity. Cardiology surveillance (LVEF, biomarkers) is modern standard. Longevity medicine complements this follow-up.
    — Curigliano et al., Eur Heart J 2020

  • Post-chemotherapy sarcopenia

    Predictor de mortalidad

    Post-chemotherapy sarcopenia (quantified with DEXA or CT) is independent predictor of mortality and toxicity. Strength training + protein intervention improves post-treatment outcomes.
    — Caan et al., JAMA Oncol 2018

  • Mental health and trajectory

    Depresión y ansiedad

    Post-diagnosis depression and anxiety are frequent — affect quality of life, treatment adherence, and longevity trajectory. Structured support is integral to modern management.
    — Mitchell et al., Lancet Oncol 2011

What we don't offer — and what we do

Wellness Care does not perform mammography, biopsy, surgery, or oncologic therapy. Mammography / MRI, biopsy, mastectomy / lumpectomy, sentinel node, chemotherapy, endocrine therapy (tamoxifen, aromatase inhibitors), targeted therapy (trastuzumab, CDK4/6), and management of established Lynch / BRCA are the responsibility of mastologist, oncologist, and geneticist. What we do: risk stratification, screening accompaniment, and modifiable factors and systemic comorbidities.

We evaluate patients with: family history of early breast / ovarian cancer (BRCA suspicion), elevated Tyrer-Cuzick / Gail score, dense breasts, postmenopausal overweight with cardiometabolic cluster, breast cancer survivors under oncology follow-up wanting to optimize post-treatment longevity trajectory (cardiotoxicity, sarcopenia, bone health, mental health). Coordination with mastology, oncology, and genetics when indicated.

Mammographic screening and BRCA identification are the specialist's competence. Modifiable factors and post-cancer trajectory are where longevity complements.
How we measure it

How breast risk is evaluated
at Wellness Care

Risk stratification + screening accompaniment + modifiable factors + systemic comorbidities. In coordination with mastology, oncology, and genetics when indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern conversation — USPSTF 2024, BRCA, IARC modifiable factors, and post-treatment cardiotoxicity.

«La USPSTF actualizó la mamografía bienal a partir de los 40 años en mujeres con riesgo promedio — respondiendo a la evidencia de reducción de mortalidad.»
USPSTF · 2024
USPSTF, 2024
Mamografía 40-74 bienal
«El riesgo a lo largo de la vida en portadoras de BRCA1 supera 60-70%, y 45-55% en BRCA2 — exige cribado intensificado y manejo multidisciplinario.»
JAMA · 2017
Kuchenbaecker et al., JAMA 2017
Riesgo en portadoras BRCA
«Obesidad postmenopáusica está clasificada por IARC como cancerígeno grupo 1 para cáncer de mama — el manejo del cluster es prevención oncológica.»
NEJM · 2016
Lauby-Secretan et al., NEJM 2016
IARC · obesidad y mama

Frequently asked questions about breast cancer

The most recurrent questions about breast cancer — screening, BRCA, modifiable factors, and why longevity medicine complements mastology and oncology.

01

At what age should I start mammography?

USPSTF 2024 recommends biennial mammography in average-risk women 40-74.

Previously recommendation started at 50 — change responds to evidence of sustained mortality reduction in 40-49 range.

If high risk:

· BRCA
· Strong family history
· Prior thoracic radiotherapy

Screening starts earlier (frequently with additional breast MRI) — mastology / oncology decision.

02

When is BRCA suspected and genetic testing requested?

BRCA testing indications per NCCN:

· Breast cancer <50
· Triple-negative breast cancer at any age
· Male breast cancer
· Ovarian cancer
· Multiple family history: breast / ovarian / aggressive prostate / pancreas
· Ashkenazi Jewish ancestry with relevant cancer

Testing includes BRCA1/2 and often expanded panel:

· PALB2
· CHEK2
· ATM
· TP53

Genetic counseling before and after is indispensable.

03

How important is alcohol as a risk factor?

Considerably.

Evidence shows a linear dose-dependent association:

· Each daily alcoholic drink increases breast cancer risk approximately 7-10%

That means even moderate consumption has measurable impact.

WHO and IARC classify alcohol as group 1 carcinogen for breast cancer.

Modern oncologic longevity conversation recognizes that no safe level of alcohol exists for breast cancer risk.

04

Does hormone replacement therapy increase the risk?

Depends on type, duration, and timing.

WHI (Rossouw 2002), Million Women Study:

· Combined therapy estrogen + progestin prolonged (>5 years) → increases breast cancer risk
· Estrogen alone (in hysterectomized women) → less impact

HRT decision is individualized:

Benefits:

· Vasomotor symptoms
· Bone health
· Quality of life

Risks:

· Breast
· Thromboembolic events

Gynecology / endocrinology decision.

05

When should I consult?

A structured assessment is worthwhile if:

· You're 40+ without up-to-date screening
· Family history of breast / ovarian / aggressive prostate / pancreas cancer
· Dense breasts (category C/D)
· Postmenopausal overweight with cardiometabolic cluster
· High alcohol consumption
· Breast cancer survivor under oncology follow-up
· Want to understand your individualized risk before decisions (HRT, late-age pregnancy)

The assessment complements mastology / oncology.

Screening + BRCA + modifiable factors

Breast cancer is the 1st global cancer incidence — but with three clear intervention axes: screening, BRCA identification, and modifiable factors.

Screen by individual risk, identify BRCA when indicated, address postmenopausal weight, alcohol, and physical activity, and coordinate with mastology, oncology, and genetics — that integration changes trajectory.

Family history or identified risk factors?

Book a comprehensive breast risk assessment

We evaluate clinical and family history (BRCA suspicion), risk score (Gail, Tyrer-Cuzick), mammographic screening indication by age and risk, modifiable factors (postmenopausal weight, alcohol, physical activity), and cardiometabolic cluster comorbidities. Does not replace mastology / oncology — it complements them.

Book breast risk assessment